A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
| ClinicalTrials.gov Identifier |
| NCT05199584 |
| Institution Name |
| Endeavor Biomedicines |
| Institution Country |
| United States |
| Additional Institutions |
| Sites are located all across the United States, with the ability to open additional locations closer to a patient's home. |
| Principal Investigator |
| Endeavor Clinical Trials |
| Principal Investigator Phone |
| (858) 727-3199 |
| Principal Investigator Email |
| ebmclinical@endeavorbiomedicines.com |
| Study Coordinator |
| Endeavor Clinical Trials |
| Study Coordinator Phone |
| (858) 727-3199 |
| Study Coordinator Email |
| ebmclinical@endeavorbiomedicines.com |
| Study Overview |
| The study drug, ENV-101, acts on a protein in the body that is thought to be involved with the growth of these abnormal cells caused by a mutation of a gene, PTCH1. By blocking this process, ENV-101 may slow the progress of the disease or you may have a partial or complete response. More Information: |
| Enrollment Information |
| Ongoing |
| Study Start Date |
| 20211201 |
| Study End Date |
| 20240531 |
| Financial Assistance Available |
| No |